Tianjin Tasly Pharma announced it will invest $40 million into a US facility that will support its TCM-based treatment for coronary disease, known as Compound Danshen Dripping Pills (CDDP). The company will build a 430,000 square foot production facility and training center near Washington DC, in a life sciences park located in Maryland. CDDP successfully completed a Phase II trial in early 2010. The company is planning a 2,000 patient Phase III trial that is expected to begin this year. More details....

Stock Symbol: (SHA: 600535)     Share this with colleagues: